Treating Macular Edema From a Retinal Vein Occlusion: What Comes First?
Macular Swelling After a Vein Occlusion at a Glance
Most of this swelling is treated calmly, in a clinic, over months. A few changes are not like that. Call your eye doctor right away, and ask for a same day slot, if you notice any of these:
- A sudden drop in vision, or sight that keeps fading hour by hour
- A curtain or shadow that moves across part of your sight
- An eye that turns red and painful, or that aches deeply
- New floaters that arrive in a shower, or new flashing lights
- Sudden double vision in one eye
In a central vein occlusion, sight can dim over a few hours or days. In severe cases the eye can hurt and feel full of pressure.1 Signs like these do not mean your eye is beyond help. They mean the plan may need to change today. Getting seen quickly is what keeps your options open.
A retinal vein occlusion is a blocked drain. Blood backs up behind the block, and fluid seeps out. When veins in the retina become blocked, blood and fluid leak into the macula, the small central patch of retina you read and recognise faces with, and the macula swells.2 That swelling is called macular edema (clinical: macular oedema). It is the swelling of the macula, rather than the blocked vein by itself, that blurs and warps the middle of your sight.2
For most people, injections come first. The American Academy of Ophthalmology names anti-VEGF drugs, given as injections into the eye, as the first line of treatment for this swelling, and describes steroid injections into the eye as having shown efficacy while carrying the risks of glaucoma and cataract.3 A steroid or a laser can still come first in specific situations, which this page walks through. Your own order is set by your retina doctor after looking at your scans.
This page explains the usual order of treatment and the reasons a doctor picks one first. It cannot tell you which treatment your eye needs, how many injections you will need, or how much sight you will get back. Those answers depend on your scans, the type of blockage, and how your eye responds over the first months. Bring this page to your visit and use it to ask sharper questions.
How a Blocked Vein Makes the Macula Swell
Behind the block, fluid and blood are pushed out through vessel walls into the retina. A chemical signal called VEGF is what keeps those vessels leaking, and it is the target of the first treatment most people are offered. Anti-VEGF treatment lowers that leaking from retinal blood vessels, and it also reduces abnormal new vessels.2 So the drugs used first are aimed at the leak, not at the clot.
A branch occlusion blocks one tributary vein, so only part of the retina floods. A central occlusion blocks the main drain, so the whole retina is affected. The distinction matters because the evidence differs. In branch occlusion, injections beat sham, laser and steroid injection for the chance of gaining vision.4 In central occlusion, anti-VEGF drugs made eyes about 2.7 times as likely as sham-treated eyes to gain at least 15 letters of vision by six months.5
A vein occlusion is usually a sign of vascular wear, not an isolated eye event. In a large population study, raised blood pressure and both stage 1 and stage 2 hypertension were each linked to a higher risk of retinal vascular occlusion. Lowering blood pressure was linked to a lower risk of a later occlusion.6 Ask which doctor is tracking your blood pressure, blood sugar and cholesterol while your eye is being treated.
Macular swelling is painless at first. When it does show itself, it blurs or warps central vision, washes out colours and makes reading hard.2 That is the pattern most people describe: not a black spot, but a smudge over the thing they are trying to look at. It is also why the whole plan aims at the fluid first, and why the first months of treatment carry the most weight.
Spotting the Swelling and Confirming It
Most people notice a blur in the middle of one eye. Straight lines can bend. Colours can look faded next to the other eye. Vision loss or blurring in part or all of one eye is the most common symptom of a central retinal vein occlusion, and it can arrive suddenly or worsen over several hours or days.1 Because one good eye hides a lot, some people only notice when they cover the better eye.
The main test is an OCT scan (clinical: optical coherence tomography). It is a light based cross section of your macula. It takes seconds, and nothing touches your eye. It shows how thick the macula is and where the fluid sits, and that thickness becomes the yardstick for later visits. Trials of these treatments track exactly that thickness, alongside the letters you read on a chart.5
Your doctor may add a fluorescein angiogram. A yellow dye goes into a vein in your arm, and a camera photographs it filling the vessels at the back of the eye. The pictures show which areas have lost their blood supply. That map matters for the plan, because a wider laser treatment is used in severe central vein occlusion, separately from anything aimed at the swelling.1
Swelling is not the only thing your doctor is watching. Abnormal new blood vessels can grow in the retina, and anti-VEGF treatment reduces them as well as the leaking.2 Eye pressure is checked at these visits too. Pressure can climb sharply within an hour of an injection7, and eyes given steroid injections had more raised pressure and more cataract than eyes given anti-VEGF.4
What Usually Comes First: Anti-VEGF Injections
They have the strongest evidence for getting vision back. In a Cochrane review of 8 trials with 1,631 people, eyes with branch occlusion swelling were more likely to gain at least 15 letters at six months with anti-VEGF than with a dummy injection or with laser, and more likely than with a steroid injection at both six and twelve months.4 Gaining fifteen letters means reading meaningfully further down the chart than before.
Numbing drops or gel go in first, then a cleaning solution, then a small holder to keep the lids open. The injection itself is a pressure or a sting lasting a second or two, and you are usually out within the hour. Eye pressure can rise within 60 minutes of an injection7, which is one reason some clinics check it before you leave. Your clinic will tell you which after effects it expects and which ones it wants to hear about.
All three block the same leak signal, and all three are given as repeated injections. They differ mainly in approval status and cost.
| Drug | Typical start | Approval and cost note |
|---|---|---|
| Aflibercept (Eylea) | Monthly injections at first | FDA-approved for swelling after a vein occlusion |
| Ranibizumab (Lucentis) | Monthly injections at first | Studied for this swelling in long-term follow-up |
| Bevacizumab (Avastin) | Monthly injections at first | Not FDA-approved for eye use, given off label, far cheaper |
The labelled dose of aflibercept for swelling after a vein occlusion is 2 mg into the eye once every 4 weeks.7 In a trial of 362 patients with a central or hemiretinal vein occlusion, treated every 4 weeks for six months, bevacizumab was noninferior to aflibercept, and both groups averaged a gain of about 19 letters.8
Expect a run of monthly visits at the start, not a single shot. The labelled schedule for aflibercept in this condition is one injection every 4 weeks.7 Ask your clinic how it decides when the gap between injections can be stretched. The choice between the original biologic drug, a biosimilar or an interchangeable version is meant to be made by the treating ophthalmologist together with the patient, since one product can suit a person better than another.3
When a Steroid or Laser Comes First Instead
Steroids work on the swelling through inflammation rather than the leak signal, and one implant lasts months rather than weeks. In trials of 1,256 people with swelling from a branch or central occlusion, about 30 of every 100 eyes gained at least 15 letters of vision 60 days after a dexamethasone implant.9 The cataract risk of these implants was measured in eyes that still had their own lens9, so ask your doctor whether it still applies to you after cataract surgery.
Grid laser places gentle burns over the leaking zone. It is a real option, mainly for branch occlusions. A Cochrane review of 5 trials with 715 people found moderate-certainty evidence from one trial supporting grid laser over simply watching, found no clear winner between grid laser and bevacizumab injections, and reported that the laser was well tolerated.10 Guidance describes laser as sometimes used in branch occlusion, rather than as the standard opening move.3
If the swelling is mild, sits off centre and your reading vision is still good, your doctor may watch first with scans every few weeks. That is a monitored plan with a trigger, not a decision to do nothing. Some eyes with a branch occlusion do settle without further injections over about four years of follow-up.11 Ask what change on the scan or the chart would start treatment, and book the follow-up before you leave.
This table sums up the trade you are being asked to weigh.
| Option | What it involves | Main trade-off |
|---|---|---|
| Anti-VEGF injections | Repeated injections, monthly at first | Many visits early on |
| Steroid implant | A tiny drug pellet placed in the eye | More cataract and pressure rise |
| Grid laser (branch only) | Light pulses over the leaking zone | Weaker effect on vision gain |
If the First Choice Does Not Work Well Enough
Two numbers drive the call: the letters you read on the chart, and the macular thickness on the scan. A good response means the thickness falls while the letters climb or hold. Those are the same two outcomes the randomised trials used to compare these treatments.4 The call is rarely made on one visit, so ask how many injections your doctor wants to see before judging the response.
If the fluid will not shift, the usual next moves are a switch to a different anti-VEGF drug or the addition of a steroid implant. One person can respond more favourably to one biologic product than to another, which is why the choice is meant to be made by doctor and patient together.3 Guidance describes steroid injections into the eye as having shown efficacy, while carrying the associated risks of glaucoma and cataract.3 A switch is part of the standard path, not a sign that you failed the treatment.
Longer than most people expect, and less forever than most people fear. Among people followed for about four years after ranibizumab treatment, the swelling had settled without further injections in 17 of 34 with a branch occlusion and in 14 of 32 with a central occlusion, while the rest still needed ongoing injections.11 Ask your own doctor what a realistic first year looks like for the type of blockage you have.
Risks, Costs and a Realistic Outlook
The feared complication is an infection inside the eye (clinical: endophthalmitis), and it is rare. A meta-analysis counted 197 infections after 350,535 injections, which is about 6 in every 10,000 injections.12 Product labelling warns that injections into the eye have been associated with endophthalmitis and retinal detachment.7 Clinics ask you to call the same day if the eye becomes red and painful with falling vision after an injection.
Steroid implants trade fewer visits for two specific costs. Over 12 months in the implant trials, cataract progressed in 90 of 302 eyes with their own lens that received two implants, against 5 of 88 sham-treated eyes, and cataract surgery was performed in 4 of those 302 eyes.9 Raised eye pressure was also more common with steroid injection than with anti-VEGF.4 Both risks are part of why injections are the usual first move for most eyes.
Averages are not promises, and your result can land either side of them. In one randomised trial of central and hemiretinal occlusions, eyes gained about 19 letters on average by month six with either drug.8 Steroid implant trials reported a gain of at least 15 letters in about 30 of every 100 eyes two months after treatment.9 Your own starting vision and scans are what your doctor will use to set your expectations.
Cost is a real part of this decision, and it is worth raising out loud. The main drivers are the drug chosen and the number of visits. In a head to head randomised trial in central and hemiretinal vein occlusion, bevacizumab given every 4 weeks was noninferior to aflibercept for vision at six months.8 Bevacizumab is repackaged for use in the eye rather than supplied in a licensed eye vial, which is why it usually costs less per dose. Ask the clinic which drug your plan covers, what the copay per injection is, and whether a patient assistance programme applies.
Protecting the Rest of Your Sight and Your Health
The eye treatment handles the swelling. It does not touch the reason the vein blocked. Higher blood pressure was linked to a higher risk of retinal vascular occlusion in a large cohort study, and lowering blood pressure was linked to a lower risk of a later occlusion.6 Book the physician appointment in the same month as your eye appointment, and take your blood pressure readings with you.
The second eye deserves attention, because the same vessels serve it. A vein occlusion can cause vision loss or blurring that arrives suddenly or worsens over several hours or days.1 So a new change in the other eye is something to report quickly rather than watch at home. Ask your doctor how often the second eye should be examined, and put the appointment in your calendar before you leave.
A home check takes ten seconds. Cover one eye, look at a door frame or a grid on the fridge, then swap eyes. You are watching for new bends, gaps or a fresh smudge. Warped central vision and difficulty reading are typical signs of macular swelling.2 Home checks do not replace scans. What they give you is a reason to phone sooner rather than wait.
Call the clinic, rather than waiting for the next slot, if your vision drops noticeably, if the eye becomes red and painful, if a shadow or curtain appears, or if new floaters or flashing lights arrive. In severe cases a central vein occlusion can cause pain and pressure in the eye.1 Most of these calls end in reassurance, and the few that do not are exactly the ones worth making.
Questions Patients Ask About Treating This Swelling
No. The injections treat the leaking and swelling that follow the blockage, not the blockage itself. That is why the stated goal is clearing fluid and holding vision, rather than reopening the vein. Anti-VEGF treatment works by reducing leaking from retinal blood vessels and reducing abnormal new vessels.2 Many eyes still do well on that basis, and some settle enough that injections stop: that happened in 17 of 34 people with a branch occlusion followed for about four years.11
Because each dose holds the leak signal down for a limited stretch, and the swelling can return as it wears off. Injections given close together at the beginning keep the fluid down long enough for the macula to settle. The labelled schedule for aflibercept in this condition is one injection every 4 weeks.7 Ask your clinic what has to happen on your scan before the gap between visits is stretched.
It is a fair question to ask directly. In a randomised trial of 362 patients with macular swelling from a central or hemiretinal vein occlusion, bevacizumab given every 4 weeks was noninferior to aflibercept for vision at six months.8 It is the cheaper option, and it is used off label in the eye, which your doctor should explain and document. Coverage rules differ between insurers, so ask what your own plan requires before the first injection rather than after it.
Longer, yes. Better for most eyes, no. Across randomised trials, eyes with branch occlusion swelling were more likely to gain at least 15 letters with anti-VEGF than with a steroid injection, at both six and twelve months.4 Guidance also notes that steroid injections carry the associated risks of glaucoma and cataract alongside their demonstrated efficacy.3 Ask your doctor whether anything about your eye or your travel makes the implant the better first move for you.
Yes, a narrower one. Grid laser remains an option for macular swelling from a branch occlusion. A Cochrane review found moderate-certainty evidence supporting grid laser over observation for that swelling, and no clear winner between grid laser and bevacizumab.10 A wider laser treatment is used separately, in severe central vein occlusion.1 Ask whether the pattern on your own scans suits laser at all.
Sooner is generally better, though your doctor sets the timing. The trials measured their benefit within six months of starting treatment, which means the clock in those studies started early. Eyes treated with anti-VEGF were about 2.7 times as likely as sham-treated eyes to gain at least 15 letters by six months in central vein occlusion trials.5 If your appointment feels far away and your sight is changing, phone the clinic and say so plainly.
More Questions About Safety, Timing and Getting Back to Normal
The serious risk is small but not zero, and the number is worth knowing. A meta-analysis found 197 infections inside the eye after 350,535 injections, roughly 6 in every 10,000.12 Labelling for these drugs warns of endophthalmitis and retinal detachment after injection.7 Soreness and a red patch on the white of the eye are the sort of thing clinics warn you about in advance. Rising pain with falling vision is the pattern that needs a same day call.
Plan for a blurry eye for a few hours, from the drops and the cleaning solution, and arrange a lift home the first time until you know how you react. Most people are back at desk work the next day. Aftercare rules differ between clinics, including what to avoid and for how long, so follow the written instructions your own unit gives you rather than general advice from a page like this one.
Some sight usually returns, but no one can promise you a full return to your old vision. Average gains in one trial were around 19 letters by six months, for central occlusion eyes treated with either of two drugs.8 Averages hide a wide spread, and an average is not a forecast for one person. Ask your doctor what your own starting vision and scans suggest is realistic.
Swelling can return quietly, without pain to warn you. Macular swelling is painless in its early stages, so it can build before you notice it.2 If you have missed visits, do not assume the chance has gone. Call and rebook, and say how long the gap has been. Your doctor can look at the current scan and tell you what is still worth doing from here.
Take these to your next appointment and write the answers down.
- Is my occlusion the branch type or the central type, and how does that change my plan?
- Which drug are you starting me on, and why that one for my eye?
- How many injections should I plan for before we judge the response?
- What would make you switch drugs or add a steroid implant?
- What is my macular thickness today, and what number are we aiming for?
- Who do I call after hours if my vision drops or the eye becomes painful?
- Which doctor is managing my blood pressure, cholesterol and blood sugar alongside this?
- American Academy of Ophthalmology (EyeSmart) (2024). What Is Central Retinal Vein Occlusion (CRVO)?.
- American Academy of Ophthalmology (EyeSmart) (2024). What Is Macular Edema?.
- American Academy of Ophthalmology (2024). Retinal Vein Occlusions Preferred Practice Pattern.
- Cochrane Database of Systematic Reviews (2020). Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
- Cochrane Database of Systematic Reviews (2014). Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
- Ophthalmology (PMID 36736752) (2023). Retinal Vascular Occlusion Risks in High Blood Pressure and the Benefits of Blood Pressure Control.
- US Food and Drug Administration prescribing information via DailyMed (2024). EYLEA (aflibercept) injection prescribing information, revised 10/2024.
- JAMA (PMID 28492910) (2017). Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
- Ophthalmology (GENEVA study group, PMID 21764136) (2011). Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results.
- Cochrane Database of Systematic Reviews (2015). Grid laser photocoagulation for macular oedema after branch retinal vein occlusion.
- Ophthalmology (PMID 24112944) (2014). Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.
- Retina (PMID 24635156) (2014). Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.